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Symposium
The Future of Reverse Payments in the
Wake of FTC v. Actavis, Inc.
Reverse payment patent litigation settlements, wherein
the payments flow from plaintiff brand name drug companies
to defendant generic competitors, often including agreements
that the generic companies will delay market entry, have
evaded consistent legal treatment and divided courts for over a
decade. In December 2012, the United States Supreme Court
granted the Federal Trade Commission’s petition for writ of
certiorari to review FTC v. Watson Pharmaceuticals. In
Watson, the Eleventh Circuit found that, absent sham
litigation or fraud, reverse payment settlements are legal
under antitrust law as long as the settlement agreement falls
within the exclusionary scope of the patent. The Watson
decision was followed mere months later by the Third Circuit’s
In re K-DUR decision, concluding that reverse-payment
settlements should be deemed presumptively unlawful under a
quick-look rule of reason approach. Because “different courts
have reached different conclusions” regarding the legality of
reverse-payment settlements, the Supreme Court endeavored
to resolve the circuit split in FTC v. Actavis, Inc.
On June 17, 2013, with Justice Breyer writing the majority
opinion in a 5-3 decision, the Supreme Court reversed the
Eleventh Circuit, holding that governments and private
plaintiffs have a cause of action under the antitrust laws
against brand name and generic pharmaceutical companies
engaging in reverse payment settlements. The Court directed
lower courts reviewing such claims to apply a full rule of reason
analysis to drug companies’ potentially anticompetitive
conduct.
In the spring of 2013, in anticipation of the Court’s
decision, the Minnesota Journal of Law, Science & Technology
invited scholars and practitioners who have analyzed and
developed the jurisprudence of reverse payment settlements to
respond to FTC v. Actavis, Inc. The following eleven response
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pieces digest the opinion, critique both Justice Breyer’s
majority opinion and Chief Justice Roberts’ dissent, and
provide direction for courts and practitioners in navigating the
new legal landscape of reverse-payment settlements in the
wake of FTC v. Actavis, Inc.
MJLST Editorial Board

